Table 5.

Progression patterns.

		All (N = 1) n (%)	BBM (N = 40) n (%)	Non-BBM (N = 6) n (%)
Patients develop progressive disease during crizotinib therapy		70 (67.3)	27 (67.5)	43 (67.2)
Progressive patterns	1#	23 (22.1)	5 (12.5)	18 (28.1)
	2#	34 (32.7)	17 (42.5)	17 (26.6)
	3#	13 (12.5)	5 (12.5)	8 (12.5)
Intracranial progression		34 (32.7)	17 (42.5)*	17 (26.6)

^*P = 0.085 vs. Non-BBM.

1#, New lesions; 2#, Regrowth of previous lesions; 3#, More than one site; BBM, baseline brain-metastases; Non-BMM, without baseline brain-metastases.